Myelodysplastic Syndromes(MDS) Clinical Trial
Official title:
Collection of Bone Marrow, Peripheral Blood (PB), Epithelial Tissue, and Saliva Samples From Patients With Myelodysplastic Syndromes (MDS) to Identify MDS-Specific Antigens (MSA) for Use in Cellular Immunotherapy.
The purpose of this study is to collect information and bone marrow, blood, saliva, cheek cells and skin to be used in the laboratory to assist the sponsor in identifying a new way of treating MDS.
Goals of the study:
The purpose of this study is to collect the blood and marrow samples, and non-involved
fibroblasts, that are required to identify the unique, personalized array of mutation-driven
neoantigens that are expressed by the subject's MDS cells and to assess the feasibility of
immunizing and expanding one or more of the patient's T cells ex vivo for investigation of
their use as adoptive cellular immunotherapy.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05709093 -
A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS)
|
Phase 3 | |
| Completed |
NCT04202003 -
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
|
Phase 1/Phase 2 |